

Making progress in our pursuit of a future free from cancer

Tēnā koutou, it is my pleasure to present the Cancer Society of New Zealand's 2024/2025 Annual Report.

We have achieved a lot this year – as seen in the following pages and Our Year in Numbers (page 4).

We have laid the foundation and set the direction for the next five years and beyond, with our new federation-wide strategic plan. We are very pleased to welcome Nicola Coom as our new Chief Executive, who is passionate about leading this.

We engaged widely, seeking the input of patients, donors, families, staff, NGOs, volunteers, and several other stakeholder groups to ensure that diverse perspectives shaped our strategy and strengthened our understanding of the challenges and opportunities ahead.

Our refreshed strategy represents our commitment to advance New Zealand towards a future free from cancer. We envision a future where if cancer can be prevented, it is. If it cannot be prevented, then it is detected early, treated quickly and patients are able to remain close to whānau and community support.

How will we achieve our dreams and aspirations?

We have clearly defined four priority areas to focus on and invest in. These are: Care in the Community; Advocacy; Research and Innovation; and Partnering for Impact. Within each priority area we have agreed on what our focus will be, what success will look like and how we enable that success, and how we will measure our impact.

Half of men and a third of women in wealthy countries can expect to suffer from cancer at some point in their lives. Worldwide, cancer is responsible for one in six deaths.

However, we are moving in the right direction in our pursuit of a future free from cancer. Since the early 1990s the age-adjusted death rate has been falling, slowly but steadily. Some wins have been extraordinary: childhood leukaemia used to be almost certainly fatal but now has a five-year survival rate above 90%. We have an opportunity to eliminate cervical cancer in New Zealand.

Much of our progress has come not through major breakthroughs, but through incremental advances – that are the result of hard work and dedication – in prevention, screening, surgery and pharmaceuticals.

It is important that we strengthen our commitment to supporting research – particularly in areas that affect New Zealand more acutely. As the largest non-government funder of research in New Zealand, we are proud to support so much life-changing work.

Thank you to our amazing staff and volunteers, donors and supporters, clinicians and researchers, and of course the patients and whānau who trust us to support them.

Ngā manaakitanga,



Julian GrennellPresident and Chair, Cancer Society of New Zealand

Turning hope into action

Stepping into the role of Chief Executive of the Cancer Society of New Zealand was a proud moment.

This is a kaupapa I care deeply about, I've had my own personal experience and lost people I love.

These experiences are at the heart of everything I do and shape every decision I make.

It's a privilege to lead an organisation that matters so much to so many.

This year has been about getting clear on our purpose, taking decisive action, and accelerating our impact.

Daffodil Day continues to unite the country. In 2024, we launched a bold new message: 1 in 3 New Zealanders will be diagnosed with cancer in their lifetime. It's a sobering truth that resonated across communities, and the country responded with incredible generosity and our biggest day yet, to ensure we can do what we do. Daffodil Day has become more than a fundraiser, it's a national movement of hope.

Our commitment to research is stronger than ever. We created a new role and appointed Christelle Jolly as our Director of Research & Innovation. We hosted our first-ever *In Pursuit* conference at Te Pae in Christchurch, bringing together local and international leaders to explore the future of cancer prevention, detection, and treatment. This year, collectively the Cancer Society invested \$4.9 million into cancer research, including five Māori-led grants administered with He Āhuru Mōwai – vital work to reduce inequities and grow a research workforce by Māori, for Māori.

In advocacy, we know every win counts. While the repeal of Smokefree legislation was a significant setback, we regrouped and continue, because it will save lives. There were also breakthroughs worth celebrating. The Government's historic \$604 million investment in modern medicines, including up to 26 new cancer treatments, representing the largest increase in our history. This milestone reflects decades of work by people across the cancer sector, pushing tirelessly for fairer access. It's a huge step forward, but New Zealand still lags behind the OECD in medicine availability, and we won't stop until this changes.

We also launched a public campaign to rally support and bring awareness to the fact that if our country chooses to we can eliminate cervical cancer. Watch this space, we're just getting started. It was a powerful moment when Professor Bev Lawton was named New Zealander of the Year for her tireless advocacy for women's health, particularly cervical screening and HPV vaccination. Her leadership inspires us.

My proudest moments this year have been spent in communities, driving patients to treatment, listening to whānau, and hearing from volunteers and donors. These conversations have guided the co-creation of our new strategy, built from the ground up by those we serve and work alongside.

Our new plan is a springboard for change, underpinned by a powerful vision: Working together towards a future free from cancer. It reflects the hope of whānau, the intention of our donors, and the determination of our people.

The year ahead is all about delivering on it, being intentional, impactful, and acting with urgency. In 2025, we're thinking big, being bolder, and moving faster.

To our long–time major sponsor ANZ — thank you. For 35 years you've stood beside us. While your Daffodil Day support shines bright, we also value the introductions, open boardrooms, and steady support you provide year–round.

We know we can't do this alone. Supporting whānau, influencing systems, advancing research, it all takes a collective effort. That's what makes the Cancer Society so special.

Thank you for standing with us. Together, we will bring about a future free from cancer.

Ngā mihi nui,



Nicola Coom

Chief Executive, Cancer Society of New Zealand

Our Year In Numbers

UPPOR.

12,757New referrals



20,609

Other client contacts (mail, email, text and video call)



7,554

Face-to-face contacts



46,639

Accommodation nights provided



49,219

Phone contacts



750,526

Kilometres driven by Cancer Society volunteers



21,699

Drives provided



12,573

Support programmes' attendees



838,784

Website page views on cancer.org.nz



2,175

Cancer Society New Zealand media mentions



\$14.85m

Total Advertising Sales Revenue (ASR) value of media mentions



30,031

Total followers on Cancer Society of New Zealand's social media channels*

EOPLE



Number of registered volunteers



Number of volunteer drivers



248

Total number of staff FTEs



85,912

Number of volunteer hours (excludes Daffodil Day)

ESEARCH





Care in the Community

The Cancer Society's strength lies in our reach. We are physically present in communities across the country allowing us to connect deeply.

Our national CSNZ team works to support our kaimahi who are out and about in the community every day, connecting families with the support they need, and advocating for change that will improve cancer outcomes.

Consistent, high-quality data allows us to speak with a unified voice about the difference we are making nationwide. It enables us to tell our story backed by evidence and ensures we can provide meaningful, measurable outcomes to those who invest in our work. For the communities we support, it means clearer communication, better service delivery, and programmes that are more responsive to local needs.

This year, the Cancer Society has made significant progress in strengthening data consistency across the Federation, an essential step in improving how we demonstrate our impact to external stakeholders, including funders, partners, and the communities we serve.

Key initiatives undertaken in 2024/25 to support this work included federation—wide data workshops. Representatives from each Cancer Society division came together to design a shared data roadmap and agree on priority areas for alignment. This has allowed us to collaborate with Impact Lab to assess our social return on investment.

These steps reflect our commitment to building a more transparent, accountable, and impact–driven organisation – one that continues to earn the trust of the public and the support of our donors.

At the Cancer Society, 'care in the community' goes beyond being physically present across Aotearoa New Zealand. It means being present everywhere people seek support – this means being accessible via the phone, on social media, in online communities and by helping cut through the noise with timely, trustworthy information.



Information at your fingertips.

As cancer increasingly affects younger demographics and our population becomes more digitally engaged, the ways people connect with care are evolving. Today, brand, data, and digital channels are not just enablers, they're also a key part of the frontline of cancer support.

The National Office plays a vital role in strengthening our Federation's ability to reach people with the right message, in the right way, at the right time.

In 2024/25, we laid the groundwork for a refreshed Cancer Society brand — designed to reflect who we are today and where we're heading. This brand work is about more than logos; it's about creating emotional connection, trust, and clarity for those navigating the cancer journey.

Looking ahead, we are developing a comprehensive channels strategy that will guide how we engage with different audiences – especially those who may not yet know us or think we're 'for them'.

As we continue this work, our presence will evolve to create content that's more tailored, timely and informed by our communities. This will mean becoming more visible in conversations that matter to the people we're here for and easier to find at the moments that count.

Digital content creation certainly took a bold step up this year with the national marketing and communications team working hard to reach and engage new audiences via our social media channels, to heighten awareness of who we are, what we do and the range of services we offer.

We launched a CSNZ TikTok channel in November, timing the launch near the start of the summer season with the aim to reach rangatahi where they are with a key focus on SunSmart behaviours. From November to March, we reached 762,000 people and ran a successful TikTok-first campaign specifically designed to encourage young people to be SunSmart. This campaign will help inform our future work in this space and was a great test of the how the channel could work for us. Going into the next financial year we are excited to continue to grow this channel and use it across all our mahi.

As part of *The Book that Ended Cancer* cervical cancer campaign we intentionally engaged with social media content creators for the first time to increase awareness of the campaign beyond our regular audience.

As we head into the new financial year we are reflecting on our learnings across our channels from last year, as well as the ever-changing social media landscape to develop a strategy to help us better reach people where they are and create pathways for new audiences to find us.



SunSmart content from CSNZ's new TikTok channel



Advocacy

The number of people diagnosed with cancer each year in Aotearoa New Zealand is about 28,000 however this number is expected to rise to more than 40,000 by 2040. We can't treat our way out of cancer, but the positive news is we could make real strides in preventing it.

It is estimated that between 30 and 50 per cent of cancer cases are preventable. With our vision to work together towards a future free from cancer, a strong focus on preventing cancer or catching it early so it is easier to treat is key.

While Cancer Society is here for all people and all cancers, we have been working hard this year helping champion the elimination of cervical cancer. Cervical cancer is the first cancer that the world has committed to eliminate.

Elimination is possible because almost all cases of cervical cancer are caused by the human papillomavirus (HPV). We have the tools now to prevent cervical cancer through HPV vaccination and HPV primary screening.

If all women and people with a cervix can access these tools, cervical cancer could be eliminated in Aotearoa New Zealand within the lifetime of today's children.

In November the Cancer Society partnered with Hei Āhuru Mōwai (Māori Cancer Leadership Aotearoa), the Royal Australian and New Zealand College of Obstetricians and Gynaecologists and Te Tātai Hauora o Hine — National Centre for Women's Health Research Aotearoa on a novel campaign to raise awareness and support for eliminating cervical cancer.



A novel campaign to raise awareness and support.



Cancer Society Chief Executive Nicola Coom talks about ending cervical cancer with Hilary Barry and Jeremy Wells from Seven Sharp.

We transformed what started life as an open letter into a book, with the catch that the story was incomplete. We invited everyday New Zealanders to go online and sign *The Book that Ended Cancer* to become a hero in the story and help us close the chapter on cervical cancer in Aotearoa New Zealand.

Our campaign attracted high-profile media coverage including a launch story on Seven Sharp, we had great support from organisations across the country spreading the word, as well as support from Cancer Society divisions encouraging signatures at summer events.

A special thank you goes out to those people who shared their personal experience of cervical cancer with us to weave those powerful stories into our mahi.

We gathered the names of nearly 4000 heroes to appear in the book, who supported our call to Government for action, with three specific requests to: extend free cervical screening; fully fund an equitable Cervical Cancer Elimination Action Plan; and urgently increase access to the human papillomavirus (HPV) vaccination. Plans are shaping up to present the book to Government shortly.

In March we celebrated one of the amazing wāhine toa we have the privilege to work with on the end cervical cancer campaign, Professor Bev Lawton, the founder/director of Te Tātai Hauora o Hine — National Centre for Women's Health Research Aotearoa, being named Kiwibank New Zealander of the Year. We are so proud to partner with Bev and her team and know she's using this platform to great effect to push for the need for a cervical cancer elimination strategy.

In March the Government agreed to lower the starting age for the National Bowel Screening Programme from 60 to 58. Health Minister Simeon Brown announced the change at the Cancer Society's In Pursuit 2025 Cancer Research and Innovation Conference in Christchurch. We acknowledged this as a 'first step' but said publicly that we must go further and faster. The Cancer Society has long recommended that population bowel screening should start at 50 years and continue to 74 years.



Health Minister Simeon Brown takes questions from media following the Government's bowel screening announcement.

We appreciate that the announcement reflected the current workforce challenges and capacity constraints of our health system. As these are addressed, we look forward to the starting age continuing to be lowered. We also emphasised that addressing equity for Māori and Pacific peoples is critical to this programme. These groups have a younger age structure, lower life expectancy and a higher proportion of bowel cancer occurring below current screening eligibility. This means these groups have less opportunity to benefit from the programme currently.

Our country has one of the highest skin cancer rates in the world and the highest rate of melanoma deaths. That's not something we want to be world-leading in.

In March we celebrated the launch of the new Skin Cancer Prevention and Early Detection Strategy 2024–2028. The Cancer Society was among a group of experts and stakeholders that collaborated on the MelNet–led strategy. Designed to coordinate action on skin cancer across a range of settings, the strategy provides a clear roadmap for tackling the significant, yet preventable, skin cancer crisis we're facing.

Acknowledging the limited investment in skin cancer prevention campaigns in recent years, we are pleased to have signed a new contract with Health New Zealand to develop a multi-year concept for a SunSmart advertising campaign. The campaign development will be informed by research we commissioned from the University of Otago exploring New Zealander's knowledge, attitudes and behaviour towards sun protection.

We celebrated the Government's commitment to improving the National Travel Assistance Scheme by delivering an \$18 million dollar uplift to the annual operating budget.

The increase in transport and accommodation rates implemented from April 2024 have made a significant difference to many families and the organisations that support them. We are still working in partnership with other NGOs to ensure all the commitments made are implemented, in particular easier prepayment and



SunSmart continues to be a key advocacy focus.

claiming options and eligibility changes to better target those with higher needs.

As New Zealand's leading cancer charity, our role is to advocate for effective cancer control laws and policies on behalf of our communities. During this annual reporting period CSNZ made seven submissions to central government, including submissions on the Smokefree Environments and Regulated Products Amendment Bill (No 2), on the review of the Food Standards Australia New Zealand Act, the review of the End-of-Life Choice Act (2019) and on the Medicines Amendment Bill (2025).

As the 24/25 financial year drew to a close we were out in market recruiting a newly established role of Head of Advocacy and Public Affairs, which was filled by Rachael Neumann, to lead our national advocacy work, shaping policy, building strategic relationships, amplifying the consumer voice and driving initiatives that reduce cancer risk and improve outcomes across the motu.



Research and Innovation

It was a significant year for research and innovation at the Cancer Society. We have supported research and innovation across the cancer continuum, from prevention and early detection to treatment and survivorship. By funding impactful research and bringing the sector together, we have built a strong foundation for a strengthened commitment for research as we work towards a future free from cancer.

We awarded three Post–Doctoral Fellowships and one PhD Scholarship as part of our 2024 National Research Grant Round. Sonesavanh Larnkham and Dr Sarah Sczelecki, researchers in the same lab at Te Herenga Waka – Victoria University of Wellington, were awarded funding to help advance the detection of ovarian cancer.

Ovarian cancer has the highest mortality rate of all gynaecological cancers in Aotearoa. Progress has been slow for the detection and treatment of ovarian cancer compared to other cancers, so we are proud to be investing in this historically under-researched area. Early diagnosis dramatically improves the survival rates. These researchers hope to identify the first screening panel of ovarian cancer biomarkers that may be used diagnostically for early detection, enabling prompt treatment and increased five-year survival rates.

Further south, two University of Otago, Christchurch researchers received funding to advance studies looking at therapies and treatment for melanoma and leukaemia. Dr Citra Praditi is looking into the role of vitamin C in melanoma, particularly understanding the role it could play as a complementary melanoma therapy. Dr Seddon hopes her study of malfunctioning mitochondria (the tiny power stations in a cell) will lead to new and better ways to treat acute myeloid leukaemia.

Five awards were made in this year's Māori Cancer Researcher Awards, with one Masters and a record four PhD Scholarships. The partnership between Te Kāhui Matepukupuku o Aotearoa (the Cancer Society of New Zealand) and Hei Āhuru Mōwai Māori Cancer Leadership Aotearoa started four years ago to award Māori cancer researchers to address health inequities and build our Māori cancer research workforce.



Sonesavanh Larnkam from Te Herenga Waka – Victoria University of Wellington is researching ovarian cancer.

It is exciting to see the partnership grow and strengthen, with the Gut Cancer Foundation joining the partnership in 2023, and this year they have helped support two of the doctoral candidates whose research will look at cancers of the digestive system. Jayde Ngata (Ngāi Tahu, Ngāti Porou) from the University of Otago, Christchurch, will lead research focused on understanding how tumour bacteria can help improve the effectiveness of immunotherapy for people with colorectal (bowel) cancer. Francesca (Ngāpuhi, Ngāti Moerewa, Ngāti Rangi, Ngāti Hine), from the University of Otago, Dunedin is focusing on understanding Māori perspectives on their tissue being used in research into gastric (stomach) cancers.

Nadine Riwai (Ngāti Porou, Te Aitanga a Māhaki, Te Uri o Hau, Ngāi Takoto, Inia) will explore mana enhancing methods to empower cancer screening programmes for Māori for her doctoral research at the University of Auckland.

Chae Phillips (Ngāti Rongomaiwahine) wants her PhD research at the University of Waikato to inform improvements in both access to care and the experiences of wāhine Māori diagnosed with symptomatic breast cancer. Chae's research will focus on developing a community-based, co-designed mātauranga Māori-informed pathway.

Gemella Reynolds-Hatem (Ngāi Tūāhuriri, Ngāti Hāteatea, Ngāti Waewae - Ngāi Tahu) from the University of Otago, Dunedin will focus her Master's scholarship on improving outcomes for whānau impacted by a CDH1 gene mutation, particularly breast cancer.

Each one of these kairangahau (researchers) is not only contributing to the academic field but is also making tangible strides towards addressing the significant health inequities faced by whānau Māori, particularly when it comes to cancer outcomes.

March 2025 was a milestone month for our research activity. We welcomed our new Director of Research & Innovation, Christelle Jolly, and established a dedicated Research and Innovation team of three within Cancer Society's national office, with Martin Witt from Cancer Society Southern joining Nicole Stanton in the national team. This underscores our commitment to increasing efforts and investment in cancer research.

We held our first national cancer research and innovation conference, In Pursuit, which was a big focal point for the year.

The event, hosted in Ōtautahi Christchurch, provided a new platform to bring groups together and consider how we can better support collaboration across the sector.

We were proud to have two of our Cancer Societyfunded researchers – Dr Annika Seddon and Dr Anastasiia Artuyants (a post–doctoral fellowship recipient from 2022) present an overview of their research projects at the pre–conference public lecture.



Gemella Reynolds-Hatem from the University of Otago Dunedin is one of this year's Māori Cancer Researcher Award recipients.

We were also delighted to be able to bring international guests Dr Catherine Elliot, Director of Research & Partnerships at Cancer Research UK, and Professor Nasir Rajpoot, whose research focuses on using AI to transform pathology, to Christchurch to speak at the conference, alongside a line-up of speakers showcasing the depth of talent we have here in New Zealand. Everyone brought their energy, expertise and bold thinking to the stage, inspiring korero sure to shape exciting next steps.

As our financial year was rounding out, researchers on both side of the Tasman were on the brink of sharing results of a practice-changing Australasian study that the Cancer Society New Zealand is proud to have supported.

The BM12 CAST trial, is a major clinical trial led by the Australasian Leukaemia & Lymphoma Group across New Zealand and Australian hospitals that is set to transform global blood stem cell transplant outcomes for people with high-risk blood cancers. Results of the trial were published in the New England Journal of Medicine and presented at the European Hematology Association 2024 Meeting in Milan Italy in June 2025.

Through a national research grant awarded to Dr Travis Perera we supported the Wellington Hospital site to open as part of this Australasian trial.

Researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukaemia significantly improves patient outcomes post-transplant, reducing the risk of the lifethreatening complication of Graft Versus Host Disease.

It is not every day that clinical trials have this level of impact. This is investigator–led research at its best — researchers thinking about how to optimise care for the benefit of patients. Clinicians have already started changing their practice to provide better and safer care for cancer patients. We are proud to have played a role in increasing access to this new approach to preventative care and congratulate all those involved.

In the year ahead we look forward to developing our first federation–wide research and innovation strategy. As the Cancer Society sets a new course in research and innovation, we're excited to build up our strengths and drive future cancer research priorities to reflect the hopes of patients and whānau.



Dr Catherine Elliot, Nicola Coom and Professor Nasir Rajpoot.



Martin Witt and Christelle Jolly talking about Cancer Society's commitment to research.



Partnering for impact

We believe we can achieve more together. It's why 'Working Together' are the words that lead our new vision.

Partnerships and collaboration are a foundation of all we do. We are incredibly grateful to our major sponsor ANZ who have stood by us for 35 years.

To progress our advocacy goals cross–sector collaboration is integral. We thank Hei Āhuru Mōwai: Māori Cancer Leadership Aotearoa, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists and Te Tātai Hauora o Hine — National Centre for Women's Health Research Aotearoa for joining with us to lead our cervical cancer elimination campaign. We also continue to lobby for improvements to the National Travel Assistance scheme with the support of our health NGO partners.

To achieve our research and innovation goals we partnered with Hei Āhuru Mōwai Māori Cancer Leadership Aotearoa and the Gut Cancer Foundation for our Māori Cancer Researcher Awards; and our In Pursuit conference had connection and collaboration as its goals.

As a charity that receives no direct government funding, we rely on the generosity of our community to support us to keep delivering our services.



Cancer Society Auckland Northland Chief Executive Andrew Young and ZM radio announcer Georgia Burt at the ANZ Donation Station.



The pick of the bunch: Daffy Jeremy Wells (centre), with Georgia Burt (left) and Hilary Barry.

This tremendous commitment is most evident in August when we hold our iconic Daffodil Day fundraising campaign and 2024 was no exception – people well and truly 'got their yellow on' to help us support the 1 in 3.

Daffodil Day is the largest annual community fundraising campaign in New Zealand and we had a record number of fundraisers, with solid growth in the number of schools signing up. The 1 in 3 theme really resonated with New Zealanders and proved a strong prompt for people to engage with.

Our major sponsor ANZ followed up 2023's Comedy Treatment fundraiser, with another winning idea – the ANZ Donation Station, held in partnership with NZME's radio stations. The special live broadcast from Auckland's iHeart Lounge featured star-studded music performances, celebrity guest appearances and epic fundraising activity with everyone pulling out all the stops to ensure its success and capping off a busy month of fundraising with a party atmosphere.

Across all national fundraising campaigns in 2024 – including Daffodil Day, Jump for Cancer, Marathon in a Month, Relay for Life, The Longest Day Golf Challenge and You Can for Cancer – over 13,000 individuals and groups actively fundraised for us, which was up by almost 3,000 on the previous year.

Just as our services are anchored in our communities, so too our fundraising efforts are driven by champions in our communities. We invite you to also check out the pages of each of our five regional Divisions' Annual Reports — available on the cancer.org.nz website — for more about fundraising activity and other highlights from the year that was.

To bolster our efforts to deepen and extend our collaborative partnerships and enhance our collective impact we established the Head of Strategic Partnerships and Funding, a key role that will see us grow our national partnerships and look to generate revenue for areas such as advocacy and research. Kris Alisch was appointed and joined CSNZ in January to take up this position. A Campaign Manager role was also established to provide strategic guidance and oversee operations for national fundraising campaigns.

We also welcomed Pania Coote (Ngāi Tahu, Ngāti Kauwhata, Ngāti Raukawa) to CSNZ as our Mana Whakahaere. Pania is a highly respected leader in Aotearoa's health and community sectors, dedicated to improving Māori health outcomes and tackling systemic inequities, and her leadership will help us foster and enhance meaningful partnerships with Māori, and embed an equity lens within all our mahi.

We know the impact and incidence of cancer is not felt equally and by uniting expertise, resources, and voices we will create stronger, more effective solutions to better serve the needs of whānau impacted by cancer.



Former Silver Ferns and other sporting legends took to the court for a Coast FM charity netball match for Daffodil Day 2024, thanks to the extensive contact book of Toni Street (far right in white).

Finances

AHUMONI

The Cancer Society is a Federation consisting of five regions with and a national office in Wellington.

The audited financial statements of Cancer Society of New Zealand Inc (consolidated with its subsidiary company Daffodil Enterprises Limited) can be found here.

These statements do not present the results or position of the whole Cancer Society Federation. While the activities of the Cancer Society presented in this report include activities of the Cancer Society of New Zealand Incorporated, the five Cancer Society Divisions, plus Cancer Society Centres and other entities that make up the Cancer Society throughout New Zealand, the results and financial positions of Divisions and Centres may be inspected through their Annual Reports or via Charities Services.



Our People

HE TANGATA

Our Board

The Board of Cancer Society New Zealand as at 31 March 2025:

- Julian Grennell (President)
- Candace Kinser
- · Chris Staynes
- Dr Garry Forgeson
- Karen Bennett
- Dr Kate Gregory (Medical Director)
- Dr Kate Reid
- · Lara Hillier (Chair, Audit Risk and Finance Committee)
- Keith Hunt

We extend our heartfelt thanks and acknowledge the contribution of those who stepped down from their volunteer director roles this year – Sue Hope, Dr George Laking (former Medical Director), Nick Dangerfield and Dr Keri Milne-Ihimaera (Manu Taki).

Our staff and volunteers

Thanks to our staff and volunteers across the motu for your amazing mahi over this year. Thanks to you the Cancer Society is firmly anchored in our communities, providing cancer support services across Aotearoa.

OUR VISION

Working together towards a future free from cancer

Te mahi tahi mō te anamata mate pukupuku kore



Te Kāhui Matepukupuku o Aotearoa

National Office
Level 13, Ranchhod Tower, 39 The Terrace, Wellington
PO Box 651, Wellington 6140
Phone (04) 494 7270 | www.cancer.org.nz

Cancer Information Helpline: 0800 CANCER (226 237)

f cancersocietyNZ | O cancersocietynewzealand | @ acancersocietynewzealand | in cancer-society-nz

SPECIAL THANKS TO OUR MAJOR SPONSOR

